Abstract

Aim: The objective of this study is to investigate the clinical efficacy of therapeutic plasma exchange in HELLP (Hemolysis, Elevated Liver Enzyme, Low Platelet) syndrome and its contribution to renal failure, an independent risk factor for maternal mortality.
Materials and Methods: Between 2019 and 2024, 20 patients diagnosed with HELLP syndrome who underwent therapeutic plasma exchange (TPE) were included. Pre-procedure and post-procedure values of the patients and the efficacy of the procedure were evaluated.
Results: The median age of the patients was 30 years (19-38) and the median number of days of TPE was 6 days (3-14). There was a statistically significant increase in hemoglobin and platelet values and a statistically significant decrease in lactate dehydrogenase, total bilirubin, direct bilirubin, aspartate aminotransferase, alanine aminotransferase, urea and creatinine values. The number of TPE sessions, length of stay in hospital and intensive care unit was significantly higher in hemodialysis patients.
Conclusion: TPE is an effective treatment modality for both clinical improvement and prevention of permanent renal failure in patients with persistent postpartum hemolysis who are followed for HELLP syndrome.

Key words: HELLP Syndrome, Therapeutic Plasma Exchange, Renal Failure